NCT04560166View on ClinicalTrials.gov

Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

September 21, 2022

Study Completion Date

September 21, 2022

Conditions
Neuroblastoma Recurrent
Interventions
DRUG

Naxitamab and GM-CSF in combination with irinotecan and temozolomide

"* Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)"

Trial Locations (3)

Unknown

Hong Kong Children's Hospital, Hong Kong

Asan Medical Center Children's Hospital, Seoul

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Y-mAbs Therapeutics

INDUSTRY